Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01107171 | Trial of Tang-min-ling Pills in the Treatment of Type 2 Diabetes | PHASE2 | COMPLETED | 210 | — | — | May 1, 2008 | Dec 1, 2008 | Apr 21, 2010 | 6 | China |
The HbA1c was measured and analyzed twice, one is before the treatment and the other is 12 weeks aftertreatment to make a self comparison.
| Arm | Type | Description |
|---|---|---|
| placebo | PLACEBO_COMPARATOR | Tang-min Lin pills analogue |
| Tang-min-ling pills high dosage | EXPERIMENTAL | Tang-min-ling pills, high dosage, 12g, tid po |
| Tang-min-ling pills low dosage | EXPERIMENTAL | low dosage group:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| Tang-min-ling pills low dosage | DRUG | low dosage:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks. |
| Tang-min-ling pills high dosage | DRUG | high dosage:12g Tang-min-ling pills every time,by 3 times every day for 12 weeks. |
| Placebo | DRUG | Tang-min-Ling pills analogue 6g,tid,po |
Inclusion Criteria: 1. Patients with primary type 2 diabetes mellitus 2. BMI ≥ 24 kg•m-2 3. 30-70 years old 4. HbA1c≥7.0%, and FPG\>7.0 mmol/L, but \<13.9 mmol/L or 2hPG\>11.1 mmol/L 5. Informed consent has been signed 6. stagnated heat of liver and stomach syndrome according to TCM syndrome differ...